Faster access than browser!
29 relations: Agranulocytosis, Alemtuzumab, Anemia, Antibody-dependent cell-mediated cytotoxicity, Boxed warning, CD20, Chronic lymphocytic leukemia, Complement-dependent cytotoxicity, Cytokine release syndrome, Diffuse large B-cell lymphoma, Fludarabine, Follicular lymphoma, Genmab, Health Canada, Hepatitis B, Leukopenia, Lymphocytopenia, Monoclonal antibody, Multiple sclerosis, Neutropenia, Ocrelizumab, Pneumonia, Progressive multifocal leukoencephalopathy, Rheumatoid arthritis, Rituximab, Sepsis, Thrombocytopenia, Tumor lysis syndrome, Urinary tract infection.
Agranulocytosis
Agranulocytosis, also known as agranulosis or granulopenia, is an acute condition involving a severe and dangerous leukopenia (lowered white blood cell count), most commonly of neutrophils causing a neutropenia in the circulating blood.
New!!: Ofatumumab and Agranulocytosis · See more »
Alemtuzumab
Alemtuzumab is a drug used in the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL) and T-cell lymphoma under the trade names Campath, MabCampath and Campath-1H, and in the treatment of multiple sclerosis as Lemtrada.
New!!: Ofatumumab and Alemtuzumab · See more »
Anemia
Anemia is a decrease in the total amount of red blood cells (RBCs) or hemoglobin in the blood, or a lowered ability of the blood to carry oxygen.
New!!: Ofatumumab and Anemia · See more »
Antibody-dependent cell-mediated cytotoxicity
The antibody-dependent cell-mediated cytotoxicity (ADCC), also referred to as antibody-dependent cellular cytotoxicity, is a mechanism of cell-mediated immune defense whereby an effector cell of the immune system actively lyses a target cell, whose membrane-surface antigens have been bound by specific antibodies.
New!!: Ofatumumab and Antibody-dependent cell-mediated cytotoxicity · See more »
Boxed warning
In the United States, a boxed warning (sometimes "black box warning", colloquially) is a type of warning that appears on the package insert for certain prescription drugs, so called because the U.S. Food and Drug Administration specifies that it is formatted with a 'box' or border around the text.
New!!: Ofatumumab and Boxed warning · See more »
CD20
B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R+, CD117+) and progressively increasing in concentration until maturity.
New!!: Ofatumumab and CD20 · See more »
Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell).
New!!: Ofatumumab and Chronic lymphocytic leukemia · See more »
Complement-dependent cytotoxicity
Complement-dependent cytotoxicity (CDC) is a function of the complement system.
New!!: Ofatumumab and Complement-dependent cytotoxicity · See more »
Cytokine release syndrome
Cytokine release syndrome is a form of systemic inflammatory response syndrome that arises as a complication of some diseases or infections, and is also an adverse effect of some monoclonal antibody drugs, as well as adoptive T-cell therapies.
New!!: Ofatumumab and Cytokine release syndrome · See more »
Diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL or DLBL) is a cancer of B cells, a type of white blood cell responsible for producing antibodies.
New!!: Ofatumumab and Diffuse large B-cell lymphoma · See more »
Fludarabine
Fludarabine, sold under the brand name Fludara among others, is a chemotherapy medication used in the treatment of leukemia and lymphoma.
New!!: Ofatumumab and Fludarabine · See more »
Follicular lymphoma
Follicular lymphoma is a type of blood cancer.
New!!: Ofatumumab and Follicular lymphoma · See more »
Genmab
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.
New!!: Ofatumumab and Genmab · See more »
Health Canada
Health Canada (Santé Canada) is the department of the government of Canada with responsibility for national public health.
New!!: Ofatumumab and Health Canada · See more »
Hepatitis B
Hepatitis B is an infectious disease caused by the hepatitis B virus (HBV) that affects the liver.
New!!: Ofatumumab and Hepatitis B · See more »
Leukopenia
Leukopenia is a decrease in the number of white blood cells (leukocytes) found in the blood, which places individuals at increased risk of infection.
New!!: Ofatumumab and Leukopenia · See more »
Lymphocytopenia
Lymphocytopenia, or lymphopenia, is the condition of having an abnormally low level of lymphocytes in the blood.
New!!: Ofatumumab and Lymphocytopenia · See more »
Monoclonal antibody
Monoclonal antibodies (mAb or moAb) are antibodies that are made by identical immune cells that are all clones of a unique parent cell.
New!!: Ofatumumab and Monoclonal antibody · See more »
Multiple sclerosis
Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged.
New!!: Ofatumumab and Multiple sclerosis · See more »
Neutropenia
Neutropenia or neutropaenia is an abnormally low concentration of neutrophils (a type of white blood cell) in the blood.
New!!: Ofatumumab and Neutropenia · See more »
Ocrelizumab
Ocrelizumab (trade name Ocrevus) is a humanized anti-CD20 monoclonal antibody.
New!!: Ofatumumab and Ocrelizumab · See more »
Pneumonia
Pneumonia is an inflammatory condition of the lung affecting primarily the small air sacs known as alveoli.
New!!: Ofatumumab and Pneumonia · See more »
Progressive multifocal leukoencephalopathy
Progressive multifocal leukoencephalopathy (PML) is a rare and usually fatal viral disease characterized by progressive damage (-pathy) or inflammation of the white matter (leuko-) of the brain (-encephalo-) at multiple locations (multifocal).
New!!: Ofatumumab and Progressive multifocal leukoencephalopathy · See more »
Rheumatoid arthritis
Rheumatoid arthritis (RA) is a long-term autoimmune disorder that primarily affects joints.
New!!: Ofatumumab and Rheumatoid arthritis · See more »
Rituximab
Rituximab, sold under the brand name Rituxan among others, is a medication used to treat certain autoimmune diseases and types of cancer.
New!!: Ofatumumab and Rituximab · See more »
Sepsis
Sepsis is a life-threatening condition that arises when the body's response to infection causes injury to its own tissues and organs.
New!!: Ofatumumab and Sepsis · See more »
Thrombocytopenia
Thrombocytopenia is a condition characterized by abnormally low levels of thrombocytes, also known as platelets, in the blood.
New!!: Ofatumumab and Thrombocytopenia · See more »
Tumor lysis syndrome
Tumor lysis syndrome (TLS) is a group of metabolic abnormalities that can occur as a complication during the treatment of cancer, where large amounts of tumor cells are killed off (lysed) at the same time by the treatment, releasing their contents into the bloodstream.
New!!: Ofatumumab and Tumor lysis syndrome · See more »
Urinary tract infection
A urinary tract infection (UTI) is an infection that affects part of the urinary tract.
New!!: Ofatumumab and Urinary tract infection · See more »
Redirects here:
ATC code L01XC10, ATCvet code QL01XC10, Arzerra, HuMax-CD20.
References
[1] https://en.wikipedia.org/wiki/Ofatumumab
